Ramona M. Rodriguiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ramona M. Rodriguiz has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- William C. Wetsel
Department of Anesthesiology, Neurology and Radiology, Duke University Medical Center, Durham, NC (H.S., W.Y., H.W., S.Z., W.W., G.A.J.).
3 shared publications - Aashish Manglik
Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA
1 shared publication - Alan Rosales
Duke University, Department of Molecular Genetics & Microbiology
1 shared publication - Allan I. Basbaum
Department of Anatomy, University of California, San Francisco, San Francisco, USA
1 shared publication Amanda Swearingen
Neurobiology Duke University School of Medicine Durham NC United States
1 shared publication- Anna Mae Diehl
Department of Medicine, Duke University, Durham, NC, USA
1 shared publication
Latest Publications
- 19 April 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (692) , eadf4086
Rescue of glutaric aciduria type I in mice by liver-directed therapies
Glutaric aciduria type I (GA-1) is an inborn error of metabolism with a severe neurological phenotype caused by the deficiency of glutaryl–coenzyme A dehydrogenase (GCDH), the last enzyme of lysine catabolism. Current literature suggests that toxic catabolites in the brain are produced locally and do not cross the blood-brain barrier. In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver. Moreover, the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches: Using an adeno-associated virus, we replaced the defective Gcdh gene or we prevented flux through the lysine degradation pathway by CRISPR deletion of the aminoadipate-semialdehyde synthase ( Aass ) gene. Our findings question the current pathophysiological understanding of GA-1 and reveal a targeted therapy for this devastating disorder.
- 19 April 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (692) , eadf4086
Rescue of glutaric aciduria type I in mice by liver-directed therapies
Glutaric aciduria type I (GA-1) is an inborn error of metabolism with a severe neurological phenotype caused by the deficiency of glutaryl–coenzyme A dehydrogenase (GCDH), the last enzyme of lysine catabolism. Current literature suggests that toxic catabolites in the brain are produced locally and do not cross the blood-brain barrier. In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver. Moreover, the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches: Using an adeno-associated virus, we replaced the defective Gcdh gene or we prevented flux through the lysine degradation pathway by CRISPR deletion of the aminoadipate-semialdehyde synthase ( Aass ) gene. Our findings question the current pathophysiological understanding of GA-1 and reveal a targeted therapy for this devastating disorder.
- Open Access
Structure-based Discovery of Conformationally Selective Inhibitors of the Serotonin Transporter
SUMMARY: The serotonin transporter (SERT) removes synaptic serotonin and is the target of anti-depressant drugs. SERT adopts three conformations: outward-open, occluded, and inward-open. All known inhibitors target the outward-open state except ibogaine, which has an unusual anti-depressant profile and stabilizes the inward-open conformation. Unfortunately, ibogaine is promiscuous and cardiotoxic, limiting understanding of inward-open state ligands. We computationally docked over 200 million small molecules against the ibogaine stabilized inward-open state of SERT. Thirty-six top-ranking compounds were synthesized and thirteen inhibited with potencies ranging from 29 to 5000 nM. Structure-based optimization led to two novel inhibitors with Ki values down to 3 nM. The new molecules stabilized an outward-closed state of the transporter and had little activity against off-targets. A cryo-EM structure of one of these bound to SERT confirmed the predicted geometry. In mouse behavioral assays, both had anxiolytic and anti-depressant activity, with potencies up to 200 better than fluoxetine.
Open AccessStructure-based Discovery of Conformationally Selective Inhibitors of the Serotonin Transporter
SUMMARY: The serotonin transporter (SERT) removes synaptic serotonin and is the target of anti-depressant drugs. SERT adopts three conformations: outward-open, occluded, and inward-open. All known inhibitors target the outward-open state except ibogaine, which has an unusual anti-depressant profile and stabilizes the inward-open conformation. Unfortunately, ibogaine is promiscuous and cardiotoxic, limiting understanding of inward-open state ligands. We computationally docked over 200 million small molecules against the ibogaine stabilized inward-open state of SERT. Thirty-six top-ranking compounds were synthesized and thirteen inhibited with potencies ranging from 29 to 5000 nM. Structure-based optimization led to two novel inhibitors with Ki values down to 3 nM. The new molecules stabilized an outward-closed state of the transporter and had little activity against off-targets. A cryo-EM structure of one of these bound to SERT confirmed the predicted geometry. In mouse behavioral assays, both had anxiolytic and anti-depressant activity, with potencies up to 200 better than fluoxetine.
- 6 April 2015
- Published by Wolters Kluwer Health in Neurology
- Vol. 84 (14_supplem)
Consequences of ATP1a3 dysfunction: Characterization of a novel model and underlying pathophysiology (S22.002)
- 6 April 2015
- Published by Wolters Kluwer Health in Neurology
- Vol. 84 (14_supplem)
Consequences of ATP1a3 dysfunction: Characterization of a novel model and underlying pathophysiology (S22.002)